Pegcetacoplan treatment prolongs foveal sensitivity and light perception in the foveal center of patients with Geographic Atrophy (GA) as measured in the Phase 3 OAKS study (EURETINA 2023 GA) - Apellis Medical Hub

Home / Congress Presentations / Geographic Atrophy / EURETINA 2023

Pegcetacoplan treatment prolongs foveal sensitivity and light perception in the foveal center of patients with Geographic Atrophy (GA) as measured in the Phase 3 OAKS study

Share Via Email

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.